Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Codexis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Codexis şirketinin toplam hissedar öz sermayesi $61.4M ve toplam borcu $28.4M olup, bu da borç-öz sermaye oranını 46.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $132.0M ve $70.6M dir.

Anahtar bilgiler

46.2%

Borç/özkaynak oranı

US$28.37m

Borç

Faiz karşılama oranı	n/a
Nakit	US$73.20m
Eşitlik	US$61.45m
Toplam yükümlülükler	US$70.56m
Toplam varlıklar	US$132.01m

Son finansal sağlık güncellemeleri

Recent updates

After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar

Jul 26

Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?

Jul 12

Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects

May 29

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

Dec 20

What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?

Dec 19

Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

Nov 15

Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S

Jun 28

Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)

Jun 07

At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?

May 09

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Feb 27

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Feb 25

Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Nov 05

Codexis appoints Kevin Norrett as chief operating officer

Oct 03

We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Aug 23

Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%

Jul 28

Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead

Jul 27

Codexis gets new executive chief

Jul 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CDXS 'nin kısa vadeli varlıkları ( $91.4M ) kısa vadeli yükümlülüklerini ( $30.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: CDXS şirketinin kısa vadeli varlıkları ( $91.4M ) uzun vadeli yükümlülüklerini ( $40.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CDXS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CDXS şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 46.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CDXS şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: CDXS serbest nakit akışı her yıl % 18 2.7 yıl yetecek nakit akışına sahip olacaktır.

Codexis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?

Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth

Recent updates

Codexis, Inc. Announces Executive Changes

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 11%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Codexis, Inc. Reiterates Earnings Guidance for the Full Year 2024

After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar

Codexis, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?

Codexis, Inc. (NasdaqGS:CDXS) entered into an asset purchase agreement to acquire Gene Therapy Assets of Crosswalk Therapeutics.

Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects

Codexis, Inc. Presents Enzymatic Synthesis Data at TIDES USA Annual Meeting and Launches RNA Ligase Screening and Optimization Services

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. Reiterates Financial Guidance for the Fiscal 2024

Codexis, Inc., Annual General Meeting, Jun 11, 2024

Codexis, Inc. to Report Q1, 2024 Results on May 02, 2024

Codexis, Inc. Appoints Carole Cobb to Its Strategic Advisory Board

Consensus revenue estimates increase by 12%

High number of new directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc Appoints Masad Damha, PhD and Jim Lalonde, PhD to Strategic Advisory Board

Codexis, Inc. Announces Not to Stand for Reelection of Jennifer Aaker as Board of Director

Codexis, Inc. announced that it expects to receive $40 million in funding

New major risk - Share price stability

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting

Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story

What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?

Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS).

Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?

Consensus EPS estimates fall by 15%

Price target decreased by 17% to US$6.20

Price target increased by 13% to US$8.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Codexis, Inc. Reiterates Earnings Guidance for the Year 2023

Codexis, Inc. to Present Update on Eco Synthesis Platform At Tides Europe

Codexis, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Codexis, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S

New minor risk - Share price stability

Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)

Price target decreased by 7.1% to US$11.14

Codexis, Inc. Unveils Eco Synthesis Platform for Large-Scale RNAi Therapeutics Production at Tides USA

At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?

Price target decreased by 10% to US$11.57

Codexis, Inc. Provides Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Director & Strategic Advisor exercised options and sold US$159k worth of stock

Director & Strategic Advisor exercised options and sold US$152k worth of stock

Chief Operating Officer recently sold US$77k worth of stock

Consensus revenue estimates decrease by 16%

Price target decreased by 8.8% to US$13.00

Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts

Director & Strategic Advisor notifies of intention to sell stock

We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Codexis, Inc. Announces Cessation of Ross Taylor as Principal Financial and Accounting Officer

Director & Strategic Advisor exercised options and sold US$159k worth of stock

Codexis, Inc. Announces Appointment of Sri Ryali as Chief Financial Officer

Codexis Appoints H. Stewart Parker to Board of Directors

Director & Strategic Advisor exercised options and sold US$132k worth of stock

Director & Strategic Advisor exercised options and sold US$157k worth of stock

Price target decreased to US$14.75

High number of new directors

Price target decreased to US$16.00

Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Codexis, Inc. Reiterates Earnings Guidance for the Year 2022

High number of new directors

Codexis, Inc. Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel

Director & Strategic Advisor notifies of intention to sell stock

Codexis, Inc. to Report Q3, 2022 Results on Nov 03, 2022